We can’t show the full text here under this license. Use the link below to read it at the source.
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
IDH mutation and MGMT gene changes in glioblastoma: findings from a forward-looking patient registry
AI simplified
Abstract
Tumors with both isocitrate dehydrogenase mutations and O6-methylguanine-DNA methyltransferase promoter methylation showed a median overall survival of 35.8 months for glioblastoma patients treated with Temozolomide and Radiation Therapy.
- Glioblastoma patients with both isocitrate dehydrogenase mutations and MGMT promoter methylation had the most favorable progression-free survival and overall survival.
- Patients with either isocitrate dehydrogenase mutations or MGMT promoter methylation exhibited intermediate outcomes.
- Wild type IDH1 glioblastomas with unmethylated MGMT promoter had the poorest survival outcomes.
- Treatment with Temozolomide plus Radiation Therapy improved overall survival and progression-free survival for wild type IDH glioblastomas compared to Radiation Therapy alone.
- Isocitrate dehydrogenase mutations appeared to confer resistance to Temozolomide, as shown by increased resistance in laboratory models.
AI simplified